Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).

Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, Cavanna L, Gori S, Fabi A, Marzano N, Graiff C, De Sanctis V, Mirabile A, Serpentini S, Bocci C, Pino MS, Cilenti G, Verusio C, Ballatori E; NICSO (Network Italiano per le Cure di Supporto in Oncologia).

Support Care Cancer. 2019 Mar;27(3):1041-1047. doi: 10.1007/s00520-018-4393-9. Epub 2018 Aug 6.

PMID:
30084104
2.

Conflict of interest among Italian medical oncologists: a national survey.

DeCensi A, Numico G, Ballatori E, Artioli F, Clerico M, Fioretto L, Livellara V, Ruggeri B, Tomirotti M, Verusio C, Roila F; Italian College of Chief Medical Oncologists (CIPOMO).

BMJ Open. 2018 Jun 30;8(6):e020912. doi: 10.1136/bmjopen-2017-020912.

3.

Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.

Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B.

Support Care Cancer. 2017 Jan;25(1):295-296. No abstract available.

PMID:
27624467
4.

2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.

Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B.

Support Care Cancer. 2017 Jan;25(1):289-294. Epub 2016 Aug 11. Erratum in: Support Care Cancer. 2017 Jan;25(1):295-296.

PMID:
27510316
5.

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.

Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F; Italian Group for Antiemetic Research.

Ann Oncol. 2015 Jun;26(6):1248-53. doi: 10.1093/annonc/mdv132. Epub 2015 Mar 5.

PMID:
25743855
6.

[Update on anticancer drugs].

Roila F, Ballatori E.

Assist Inferm Ric. 2014 Apr-Jun;33(2):97-115. doi: 10.1702/1539.16817. Review. Italian.

PMID:
25002061
7.

Reply to T.L. Ng et al and L. Celio et al.

Roila F, Fatigoni S, Ballatori E.

J Clin Oncol. 2014 Jul 10;32(20):2187-8. doi: 10.1200/JCO.2014.55.8197. Epub 2014 Jun 9. No abstract available.

PMID:
24912894
8.

Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.

Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M.

J Clin Oncol. 2014 Jan 10;32(2):101-6. doi: 10.1200/JCO.2013.51.4547. Epub 2013 Dec 9.

PMID:
24323030
9.

Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.

Olver I, Clark-Snow RA, Ballatori E, Espersen BT, Bria E, Jordan K.

Support Care Cancer. 2011 Mar;19 Suppl 1:S33-6. doi: 10.1007/s00520-010-0985-8. Epub 2010 Aug 29.

PMID:
20803222
10.

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.

Kris MG, Tonato M, Bria E, Ballatori E, Espersen B, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Saito M, Morrow G, Hesketh P.

Support Care Cancer. 2011 Mar;19 Suppl 1:S25-32. doi: 10.1007/s00520-010-0976-9. Epub 2010 Aug 28.

PMID:
20803039
11.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v232-43. doi: 10.1093/annonc/mdq194. Review. No abstract available.

PMID:
20555089
12.

Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey.

Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM).

Tumori. 2009 Nov-Dec;95(6):647-51.

PMID:
20210223
13.

Treatment of lung cancer.

Ballatori E, Fatigoni S, Roila F.

N Engl J Med. 2009 Dec 17;361(25):2485; author reply 2486-7. doi: 10.1056/NEJMc0909634. No abstract available.

PMID:
20018971
14.

Cetuximab for metastatic colorectal cancer.

Roila F, Garassino MC, Ballatori E.

N Engl J Med. 2009 Jul 2;361(1):95; author reply 96-7. No abstract available.

PMID:
19579279
15.

[Methodology of pharmacoeconomic studies in oncology].

Ballatori E.

Recenti Prog Med. 2008 Jan;99(1):42-7. Review. Italian.

PMID:
18389873
16.

Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials.

Ballatori E, Roila F, Ruggeri B, De Angelis V, Porzio G, Marchetti P; Italian Group for Antiemetic Research.

Tumori. 2007 Nov-Dec;93(6):540-3.

PMID:
18338486
17.

Is there still a role for the uniscale assessment of quality of life?

Ballatori E, Porzio G, Roila F, Ruggeri B, Mattei A, Cortesi E.

Tumori. 2007 Jan-Feb;93(1):78-81.

PMID:
17455876
18.

The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.

Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR.

Support Care Cancer. 2007 Feb;15(2):179-85. Epub 2006 Aug 29.

PMID:
16941136
19.

Dental caries and bone mineral density: a cross sectional study.

Fabiani L, Mosca G, Giannini D, Giuliani AR, Farello G, Marci MC, Ballatori E.

Eur J Paediatr Dent. 2006 Jun;7(2):67-72.

PMID:
16842026
20.

The cost of chemotherapy-induced nausea and vomiting in Italy.

Ballatori E, Roila F, Ruggeri B, Porrozzi S, Iannopollo M, Soru G, Cruciani G, Daniele B, Locatelli MC, Pellissier J, Deuson R.

Support Care Cancer. 2007 Jan;15(1):31-8. Epub 2006 Jun 21.

PMID:
16788840
21.

Emesis induced by low or minimal emetic risk chemotherapy.

Tonato M, Clark-Snow RA, Osoba D, Del Favero A, Ballatori E, Borjeson S.

Support Care Cancer. 2005 Feb;13(2):109-11. Epub 2004 Nov 18. Review.

PMID:
15714358
22.

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E.

Support Care Cancer. 2005 Feb;13(2):85-96. Epub 2004 Nov 23. Review. Erratum in: Support Care Cancer. 2005 Jul;13(7):562. Dosage error in article text.

PMID:
15565277
23.

[Methodology of drug utilization studies].

Ballatori E, Roila F, Ruggeri B.

Suppl Tumori. 2004 Jul-Aug;3(4):S83-5. Italian. No abstract available.

PMID:
15206222
24.

[Emerging clinical research problems in oncology].

Roila F, Ballatori E, Del Favero A.

Suppl Tumori. 2004 Jul-Aug;3(4):S35-6. Italian. No abstract available.

PMID:
15206207
25.

Improving information to Italian cancer patients: results of a randomized study.

De Lorenzo F, Ballatori E, Di Costanzo F, Giacalone A, Ruggeri B, Tirelli U.

Ann Oncol. 2004 May;15(5):721-5.

PMID:
15111338
26.

Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.

Ballatori E, Roila F.

Health Qual Life Outcomes. 2003 Sep 17;1:46. Review.

27.

Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy.

Roila F, Ballatori E, Patoia L, Palazzo S, Veronesi A, Frassoldati A, Cetto G, Cinieri S, Goldhirsch A; Drug Utilization Rview Team in Oncology.

Ann Oncol. 2003 Jun;14(6):843-8.

PMID:
12796020
28.

Quality of life: gynaecological cancers.

Pignata S, Ballatori E, Favalli G, Scambia G.

Ann Oncol. 2001;12 Suppl 3:S37-42. Review.

PMID:
11804383
29.

Unsolved problems in evaluating the quality of life of cancer patients.

Ballatori E.

Ann Oncol. 2001;12 Suppl 3:S11-3.

PMID:
11804377
30.

Docetaxel as second-line chemotherapy for non-small-cell lung cancer.

Roila F, Del Favero A, Ballatori E.

J Clin Oncol. 2000 Nov 1;18(21):3738-9. No abstract available.

PMID:
11054450
31.

Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO).

Costantini M, Mencaglia E, Giulio PD, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, Licitra L, Candis DD, Massidda B, Luzzani M, Campora E, Placido SD, Palmeri S, Angela PM, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L.

Qual Life Res. 2000 Mar;9(2):151-9.

PMID:
10983479
32.

Studies on new antiemetic drugs.

Roila F, Tonato M, Ballatori E, Del Favero A.

J Clin Oncol. 1999 Jun;17(6):1960-2. No abstract available.

PMID:
10561240
33.

Gemcitabine: a real major advance?

Roila F, Del Favero A, Ballatori E.

Ann Oncol. 1999 May;10(5):609-10. No abstract available.

PMID:
10416016
34.

[Planning a statistical inquiry for evaluation of patient information].

Bernardini C, Ambrogi V, Fardella G, Perioli L, Tiralti MC, Ballatori E.

Boll Chim Farm. 1999 Mar;138(3):57-67. Italian.

PMID:
10394704
35.

Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist.

Roila F, Ballatori E, Del Favero A.

N Engl J Med. 1999 Jun 17;340(24):1926-8. No abstract available.

PMID:
10375317
36.

The efficacy and cost-effectiveness of various antiemetic regimens.

Roila F, Ballatori E.

Curr Opin Oncol. 1998 Jul;10(4):310-5. Review.

PMID:
9702398
37.

Statistical considerations in the design, conduct and analyses of antiemetic clinical trials. An emerging consensus.

Morrow GR, Ballatori E, Groshen S, Olver I.

Support Care Cancer. 1998 May;6(3):261-5. Review.

PMID:
9629880
38.

Clinical benefit as a primary efficacy endpoint.

Ballatori E, Del Favero A, Roila F.

J Clin Oncol. 1998 Feb;16(2):803-4. No abstract available.

PMID:
9469377
39.

5-HT3 receptor antagonists: differences and similarities.

Roila F, Ballatori E, Tonato M, Del Favero A.

Eur J Cancer. 1997 Aug;33(9):1364-70. Review.

PMID:
9337675
40.

Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer.

Ballatori E, Roila F, De Angelis V, Ciccarese G, Palladino MA, Tonato M, Del Favero A, Herrstedt J, Dicato M, du Bois A, Hesketh P, Kris M, Gralla RJ.

Support Care Cancer. 1997 Jul;5(4):269-73.

PMID:
9257422
41.

The control of delayed nausea.

Roila F, Ballatori E.

Ann Oncol. 1997 Jun;8(6):615-6. No abstract available.

PMID:
9261534
42.

[Evaluation of quality of life in oncology. Rationale and objectives of the first phase of the Quality of Life in Oncology project].

Costantini M, Mencaglia E, Di Giulio P, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, Licitra L, Massidda B, Luzzani M, Campora E, De Placido S, Palmeri S, Palladino MA, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L.

Tumori. 1997;83(2 Suppl):S25-7. Italian.

PMID:
9235726
43.

Methodology of trials with antiemetics.

Tonato M, Roila F, Del Favero A, Ballatori E.

Support Care Cancer. 1996 Jul;4(4):281-6. Review.

PMID:
8829305
44.

Comparative studies of various antiemetic regimens.

Roila F, Tonato M, Ballatori E, Del Favero A.

Support Care Cancer. 1996 Jul;4(4):270-80. Review.

PMID:
8829304
45.

Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Tonato M, Roila F, Del Favero A, Ballatori E.

Support Care Cancer. 1994 May;2(3):150-60. Review.

PMID:
8032700
46.

Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.

Ballatori E, Roila F, Berto P, De Angelis V, Neri C, Olivieri A, Tonato M, Del Favero A.

Pharmacoeconomics. 1994 Mar;5(3):227-37.

PMID:
10146897
47.

Antiemetic therapy: the state of the art.

Roila F, Ballatori E, Del Favero A.

Ann Oncol. 1993 Nov;4(9):795. No abstract available.

PMID:
8280664
48.

Antiemetic effects of ondansetron and metopimazine.

Roila F, Ballatori E, Del Favero A.

N Engl J Med. 1993 Oct 28;329(18):1356-7. No abstract available.

PMID:
8413427
49.

Reliability and validity of a quality of life questionnaire in cancer patients.

Ballatori E, Roila F, Basurto C, Bracarda S, Picciafuoco M, Soldani M, Crinò L, Tonato M, Milella G, Del Favero A.

Eur J Cancer. 1993;29A Suppl 1:S63-9.

PMID:
8427728
50.

Ondansetron.

Roila F, Tonato M, Basurto C, Bracarda S, Sassi M, Lupattelli M, Picciafuoco M, Ballatori E, Del Favero A.

Eur J Cancer. 1993;29A Suppl 1:S16-21. Review.

PMID:
8427720

Supplemental Content

Loading ...
Support Center